No abstract available
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Drug Resistance, Neoplasm / genetics*
-
Exons / genetics
-
Female
-
Humans
-
Imidazoles / administration & dosage*
-
MAP Kinase Kinase Kinases / antagonists & inhibitors
-
Male
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Melanoma / pathology
-
Middle Aged
-
Mutation
-
Neoplasm Metastasis
-
Oximes / administration & dosage*
-
Protein Kinase Inhibitors / administration & dosage
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Proto-Oncogene Proteins B-raf / genetics*
-
Pyridones / administration & dosage*
-
Pyrimidinones / administration & dosage*
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / genetics
-
Skin Neoplasms / pathology
-
Treatment Outcome
Substances
-
Imidazoles
-
Oximes
-
Protein Kinase Inhibitors
-
Pyridones
-
Pyrimidinones
-
trametinib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
MAP Kinase Kinase Kinases
-
dabrafenib